Stock Markets February 19, 2026

PMGC Holdings Shares Jump After Subsidiary Files Ten U.S. Patent Applications

NorthStrive Biosciences seeks protection for EL-22 and EL-32 applications across livestock, aquaculture and poultry; stock lifts in premarket trading

By Leila Farooq ELAB
PMGC Holdings Shares Jump After Subsidiary Files Ten U.S. Patent Applications
ELAB

PMGC Holdings Inc saw a premarket gain of 9.8% after its subsidiary, NorthStrive Biosciences, filed ten U.S. patent applications for EL-22 and EL-32 technologies aimed at muscle growth in farmed animals and emissions reduction in livestock and aquaculture. The filings span multiple species and describe non-feed additive supplements and other approaches to improve muscle yield and environmental outcomes.

Key Points

  • PMGC stock rose 9.8% in premarket trading following NorthStrive Biosciences filing of ten U.S. patent applications.
  • Five applications cover EL-22 and five cover EL-32, targeting muscle growth and emissions reduction across livestock, aquaculture and poultry.
  • NorthStrive is a wholly owned subsidiary focused on aesthetic medicines; EL-22 is described as an engineered probiotic to preserve muscle during weight loss treatments, including with GLP-1 receptor agonists.

Summary

PMGC Holdings Inc experienced a 9.8% rise in premarket trading after NorthStrive Biosciences, a wholly owned subsidiary, submitted ten U.S. patent applications covering its proprietary EL-22 and EL-32 technologies. The filings target animal health and agricultural applications, including livestock, aquaculture and poultry, and describe approaches intended to increase muscle growth and reduce emissions.


Details of the filings

NorthStrive submitted a total of ten patent applications in the United States - five directed to EL-22 and five directed to EL-32. According to the filings described by the company, the technologies are intended as non-feed additive supplements to encourage animals to generate new muscle tissue and to increase muscle weight return on a per-animal basis.

The applications encompass multiple farmed animal categories. In aquaculture, the patents focus on methods or technologies that could shorten the time required for animals to reach commercially viable size and reduce energy costs. For poultry, the filings address improving muscle growth and boosting muscle yield per bird within normal growth timelines. Additional patent claims described by the company include measures designed to reduce emissions from livestock and aquaculture operations, suggesting an environmental component to the technology suite.


Company focus and assets

NorthStrive Biosciences is identified as a wholly owned subsidiary of PMGC Holdings and is described as focusing on the development of aesthetic medicines. The company lists EL-22 as its lead asset and characterizes its approach as an engineered probiotic aimed at preserving muscle during weight loss treatments, including in conjunction with GLP-1 receptor agonists.

PMGC Holdings characterizes itself as a diversified holding company that manages and grows its portfolio through strategic acquisitions, investments and development across various industries.


Implications for markets and sectors

The filings extend the company’s stated technological reach into animal health, agriculture, aquaculture and poultry sectors while also touching on environmental emissions concerns tied to farming and aquaculture operations. The premarket stock move reflects investor reaction to the intellectual property expansion.

Risks

  • The filings are patent applications; the article does not provide information on approval status, timing, or the likelihood these applications will be granted - this creates uncertainty about legal protection and commercial exclusivity. (Impacted sectors: biotech, animal health, agriculture).
  • The article does not state commercial readiness, deployment timelines, or demonstrated efficacy in target animal markets, leaving unclear how and when the technologies might affect production or revenues. (Impacted sectors: agriculture, aquaculture, poultry).
  • No financial impacts, revenue projections or guidance tied to the patent filings are provided in the article, so the effect on PMGC Holdings future financials remains undetermined. (Impacted sectors: capital markets, investors).

More from Stock Markets

Supreme Court Reviews Broad Array of Trump-Era Policies Across Trade, Immigration and Federal Workforce Feb 20, 2026 Toymakers Weigh Options After Supreme Court Nixes Emergency Tariffs Feb 20, 2026 OpenAI Narrows Long-Range Compute Plan to $600 Billion, Reframes Growth to Revenue-Linked Spending Feb 20, 2026 Moody's Moves Amazon Outlook to Stable as Company Embarks on Massive AI-Driven Capex Push Feb 20, 2026 Phil Spencer to Retire After 38 Years; Asha Sharma Named CEO of Microsoft Gaming Feb 20, 2026